NASDAQ · OVID
Ovid Therapeutics Inc.
$2.56+$0.11 (+4.49%)
Ovid Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.68% below the high.
Loading market information…
NASDAQ · PLRX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pliant Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pliant Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.37. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pliant Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 3, 2025 | -$0.82+17.17% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.95+4.04% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.56+$0.11 (+4.49%)
Ovid Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.68% below the high.
$4.23-$0.05 (-1.05%)
Artiva Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.89% below the high.
$3.30-$0.16 (-4.62%)
Whitehawk Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$9.14-$0.15 (-1.61%)
Sutro Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.16% below the high.
$1.99-$0.07 (-3.4%)
Zentalis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.37% below the high.
$4.36$0.00 (0.0%)
Adverum Biotechnologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.17% below the high.
$3.98-$0.08 (-1.97%)
Coya Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.88% below the high.
